⚡ Interrogation des APIs scientifiques en cours…
⚡ Interrogation des APIs scientifiques en cours…
Authors' conclusion
Does not affect the score
Publi-Score
Fidelity
Abstract (PubMed)
SUSTAIN-6: RCT regulatory CVOT, N=3297 T2D patients at high CV risk (83% with established CVD/CKD), semaglutide 0.5 or 1.0 mg/week vs placebo, 104 weeks. Primary MACE outcome: HR 0.74 (95% CI 0.58–0.95; P<0.001 for non-inferiority). Non-fatal stroke HR 0.61 (0.38–0.99; P=0.04). Non-fatal MI HR 0.74 (0.51–1.08; P=0.12 NS). Funded by Novo Nordisk.
Coeff. authors = avg(0.85, 0.70) = 0.77
Coeff. editorial = avg(1.00, 0.90) = 0.95
min(0.77, 0.95) = 0.77← lowest dominates
Final coefficient : 0.77
Final score = 46.7/52.8 × 0.77 × 100 = 69/100
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff AM — 2023 · The New England Journal of Medicine
Contrasted resultsCardiovascular Disease, Drug Therapy, and Mortality in Covid-19.
Mehra MR — 2020 · The New England Journal of Medicine
Contrasted resultsCardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Bhatt DL — 2018 · The New England journal of medicine
Contrasted resultsSaturated fat, carbohydrate, and cardiovascular disease.
Siri-Tarino PW — 2010 · The American journal of clinical nutrition
Contrasted resultsSleep apnea and cardiovascular disease: an American Heart Association/American College …
Somers VK — 2008 · Journal of the American College of Cardiology